Akari Therapeutics, Plc
AKTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Akari Therapeutics, Plc (AKTX) is listed under Biotechnology. At a $18.8M market cap, Akari Therapeutics, Plc ranks as a micro-cap company within healthcare. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Market Cap
$18.8M
Beta
1.44
P/E (TTM)
—
P/E (Fwd)
-0.95
EPS (TTM)
$0.00
EPS (Fwd)
$-8.65
ROE
-140.1%
ROA
-19.1%
Cash
$7.7M
Total Debt
$693,000
Free CF
-$9.4M
52W Change
-74.1%
Annual Financials
Cash vs Debt
Where AKTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AKTX finished 11.50% above its 150-day moving average ($8.87) and 7.62% above its 200-day moving average ($9.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AKTX overbought or oversold?
At the October 20, 2026 close, AKTX's RSI(14) was 51.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Akari Therapeutics, Plc holds $7.7M in cash against $693K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$9.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -140.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, AKTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Akari Therapeutics, Plc's trajectory.